RenuGel
PreclinicalSmall molecule
RenuGel is one of 18 small molecule programs targeting Tremor. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
21 competitors in Tremor
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Neurontin
VViatris Specialty LLC
Phase 3
Topamax
WWim Janssens
Phase 3
Xyrem
Jazz PharmaceuticalsPhase 2
Epidiolex
Jazz PharmaceuticalsPhase 2
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 2
Onabotulinumtoxin a
LundbeckPhase 2
Alcohol
AstellasPhase 2
Abobotulinum Toxin a
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Approved
Bont-a
SSir Run Run Shaw Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RenuGel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details